Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Income from Continuing Operations of 60825000.0 for Q1 2026, down 129.75% on a QoQ basis from 204452000.0 in Q4 2025, and little changed year-over-year from 60896166.14 in Q1 2025.
Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 60825000.0 for Q1 2026.
- Quarterly Income from Continuing Operations changed 0.12% year-over-year to 60825000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5549000.0 (up 102.73% YoY) and the FY2025 annual result came in at 5646000.0, up 103.34% from the prior year.
- Income from Continuing Operations was 60825000.0 for Q1 2026 at Bicycle Therapeutics, down from 204452000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 204452000.0 in Q4 2025 and bottomed at 78983000.0 in Q2 2025.
- A 5-year average of 19810705.88 and a median of 39797000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations jumped 517.79% — and 2024, when it sank 138.72%.
- Bicycle Therapeutics' Income from Continuing Operations stood at 32036000.0 in 2022, then soared by 517.79% to 133844000.0 in 2023, then sank by 138.72% to 51819000.0 in 2024, then surged by 494.55% to 204452000.0 in 2025, then sank by 129.75% to 60825000.0 in 2026.
- Business Quant data shows BCYC's Income from Continuing Operations at 60825000.0 in Q1 2026, 204452000.0 in Q4 2025, and 59095000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Bicycle Therapeutics | 272.11 Mn | 272.11 Mn | - | -60.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.83 Mn |
| Dec 31, 2025 | 204.45 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.98 Mn |
| Mar 31, 2025 | -60.75 Mn |
| Dec 31, 2024 | -51.82 Mn |
| Sep 30, 2024 | -50.80 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Mar 31, 2024 | -26.51 Mn |
| Dec 31, 2023 | 133.84 Mn |
| Sep 30, 2023 | -49.93 Mn |
| Jun 30, 2023 | -42.60 Mn |
| Mar 31, 2023 | -39.08 Mn |
| Dec 31, 2022 | -32.04 Mn |
| Sep 30, 2022 | -28.39 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -17.99 Mn |
| Sep 30, 2021 | -14.69 Mn |
| Jun 30, 2021 | -17.87 Mn |